Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Myriad Genetics's EBIT per Share for the
three
months ended in Mar. 2026 was €-0.28.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-3.61.
During the past 3 years, the average EBIT per Share Growth Rate was 21.90% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 15.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Myriad Genetics's EBIT per Share or its related term are showing as below:
STU:MYD'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -63.7 Med: -3.9 Max: 37.6
Current: 21.9
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Myriad Genetics was 37.60% per year. The lowest was -63.70% per year. And the median was -3.90% per year.
STU:MYD's 3-Year EBIT Growth Rate is ranked better than 60% of 165
companies
in the Medical Diagnostics & Research industry
Industry Median: 13.2
vs STU:MYD: 21.90
Myriad Genetics's EBIT for the
three
months ended in Mar. 2026 was €-26.0 Mil.
Myriad Genetics (STU:MYD) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Myriad Genetics EBIT per Share Related Terms
Myriad Genetics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Myriad Genetics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.61
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myriad Genetics (STU:MYD) has a EBIT per Share of €-3.61 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Myriad Genetics and its competitors. According to the industry distribution chart, Myriad Genetics ranks #66 out of 165 companies in the Medical Diagnostics & Research industry, placing it in the top 40%.
Is Myriad Genetics' EBIT per Share too high?
Myriad Genetics' current EBIT per Share is €-3.61. Based on the distribution chart, Myriad Genetics ranks #66 out of 165 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Myriad Genetics has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' EBIT per Share compare to FLGT and CSTL?
According to the Medical Diagnostics & Research industry distribution chart, Myriad Genetics ranks #66 out of 165 companies for EBIT per Share. This puts Myriad Genetics in the upper half of its industry. The industry median EBIT per Share is 13.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.20, based on 165 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Myriad Genetics and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Myriad Genetics's current EBIT per Share is €-3.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €13.22, compared to a current price of €5.26 — trading 60.2% below its estimated fair value. The current EBIT per Share is €-3.61. Myriad Genetics' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current EBIT per Share is €-3.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myriad Genetics (STU:MYD) Overvalued in 2026?
Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued.
The current stock price of €5.26 is trading 60.2% below its estimated GF Value™ of €13.22.
GuruFocus considers Myriad Genetics to be Possible Value Trap.
Key valuation signals for STU:MYD:
EBIT per Share: €-3.61
GF Value™: €13.22 vs. price of €5.26 (60.2% below fair value)
No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
54GF Score
Get the complete analysis for STU:MYD
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MYD has been successfully added to your 
